Anish M. John - 24 Feb 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Financial Officer
Signature
/s/ Anish John
Issuer symbol
OCX
Transactions as of
24 Feb 2023
Net transactions value
$0
Form type
4
Filing time
28 Feb 2023, 16:55:59 UTC
Previous filing
19 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +121,381 $0.000000 121,381 24 Feb 2023 Common Stock 121,381 $0.3900 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One third of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.